Ospedale San Giovanni Bosco — Clinical Trial Site

21 Registered trials

9 Currently recruiting

Organisation

Ospedale San Giovanni Bosco

Location

Turin, Italy

Identifier

ORG-100029788

Address

Piazza Del Donatore Di Sangue 3, 10154, Italy

Departments

#2126: S.C. Nefrologia e Dialisi - CMID
Head and Neck Cancer Unit
Nephrology
ONCOLOGIA MEDICA
SC Neurology
SC Oncologia Medica
SCdU Nefrologia e Dialisi
ScdU Nefrologia e Dialisi - CMID
SCdU Nefrologia e Dialisi -CMID
SCdU Nefrologia e Dialisi- CMID
SCDU Nephrology and Dialysis
SCdU Nephrology and Dyalisis - CMID
SSD di Ematologia e Malattie Trombotiche
UO Nefrologia

Clinical trials at this site (21)

Search interface

A Phase II, Open-Label, Single-Arm, Multicentre Study of Carboplatin, Paclitaxel, and Tislelizumab in Biomarker-Selected Patients with Resec… Pending

2024-517565-16-00 Resectable Locally Advanced Oral Cavity Squamous Cell C 4
A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY… Pending

2024-517861-18-00 Idiopathic IgA nephropathy (IgAN) 5
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-… Recruiting

2024-511346-39-00 Immune-mediated necrotizing myopathy 3 2025-03-28
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
A Phase 3 Study of Obexelimab in Patients with IgG4-Related Disease Recruiting

2022-500718-24-00 IgG4-Related Disease 5 2023-06-09
A Study to understand the Effectiveness, Safety, and what the body does to Mosunetuzumab in participants with Systemic Lupus Erythematosus w… Recruiting

2024-519930-22-00 Systemic Lupus Erythematosus (SLE) With or Without Acti 4 2026-05-18
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting

2024-519345-30-00 IgA nephropathy 5 2025-11-12
Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) Recruiting

2023-507692-21-00 Bullous pemphigoid 3 2024-08-22
A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR) Recruiting

2024-513562-19-00 End-Stage Kidney Disease 5 2023-08-30
A Randomized & Observational phase II trial comparing the activity of TrabectedIn vs gemCitabine in patients with metastatic or locally adva… Recruiting

2024-513820-40-00 Metastatic or locally advanced leiomyosarcoma 4 2021-10-29
NeoAspMet - Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced recta… Recruiting

2024-519007-10-00 Locally advanced stage II/III rectal cancer 10 2020-10-22
A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended

2023-506669-70-00 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR- 5 2024-04-30
A Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephr… Ended

2022-502102-32-00 Primary Immunoglobulin A (IgA) Nephropathy 5 2023-11-16
Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n… Ended

2023-508559-37-00 Lupus nephritis 5 2022-07-14
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis Ended

2023-504597-37-00 Focal segmental glomerulosclerosis 5 2022-03-25
A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy Ended

2023-506525-11-00 Primary Membranous Nephropathy (pMN) 5 2021-04-19
Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cel… Ended

2024-511637-35-00 Elderly patients with Diffuse Large B-Cell Lymphoma (DL 5 2021-03-23
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease. Ended

2023-508290-81-00 Immunoglobulin G4-related disease (IgG4-RD) 5 2020-12-18
A study evaluating the effects of GLPG3667 given as oral treatment for up to 24 weeks in adults with dermatomyositis Ended

2022-501097-19-00 dermatomyositis 4 2023-08-09
Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended

2023-504825-38-00 Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN 4 2022-04-15
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended

2023-507977-16-00 Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN 4 2021-05-10